Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > classes : Phenethylamine or Stimulant or [[:Category:Antimanic medicines|Antimanic]]

Use the filters below to narrow your results.

generic:
brand:
None (67) · Benzedrex (1) · Lithobid (extended-release); Eskalith (discontinued in US); Carbolith (Canada); Priadel (UK); Camcolit (UK) (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (12) · Monoamine releasing agent (8) · Dopamine/norepinephrine reuptake inhibitor (5) · Potent 5-HT2A agonist (5) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · Norepinephrine–dopamine reuptake inhibitor (2)
uses:
None (70)
starting dose:
None (70)
preparations:
None (69) · Lithium carbonate: immediate-release capsules (150 mg, 300 mg, 600 mg) and tablets (300 mg); extended-release tablets (300 mg, 450 mg). Lithium citrate: oral solution (8 mEq/5 mL, equivalent to 300 mg lithium carbonate per 5 mL) for patients unable to swallow tablets. (1)
fda max:
None (69) · No defined absolute maximum; dosing is guided by serum level monitoring. Levels above 1.5 mEq/L carry increasing toxicity risk. Levels consistently above 1.2 mEq/L are generally not maintained in clinical practice.'"`UNIQ--ref-00000052-QINU`"' (1)
routes:
None (68) · insufflated (1) · Oral (2) · PR (1)
onset:
None (68) · 45-75 min (oral) (1) · Antimanic effects begin within 5-7 days of reaching therapeutic serum levels, with full response often requiring 2-3 weeks. For acute mania, a neuroleptic is typically added for rapid sedation while lithium takes effect.'"`UNIQ--ref-00000053-QINU`"' (1)
duration:
None (69) · 4-8 h (1)
halflife:
None (68) · Approximately 18-24 hours after acute administration; may extend to 36-48 hours with chronic dosing as tissue compartments equilibrate. Serum trough levels should be drawn 12 hours after the last dose for accurate interpretation.'"`UNIQ--ref-00000055-QINU`"' (1) · Not well characterized (1)
bioavailability:
None (69) · Not well characterized (1)
pregnancy:
None (69) · Not established (1)
legal:
None (68) · Not a controlled substance in the United States, European Union, United Kingdom, Canada, or Australia. Prescription-only in all of these jurisdictions due to the narrow therapeutic index and the need for serum monitoring. No abuse potential has been identified. (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)

Showing below up to 70 results in range #1 to #70.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"